Celularity Inc. Regains Nasdaq Bid-Price and Market-Value Compliance

What Happened
On September 11, 2026, Celularity Inc. (CELU) received written notifications from the Nasdaq Listing Qualifications Staff confirming the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2). Celularity filed the Form 8-K on September 14, 2026. Nasdaq advised Celularity that each of those matters is now closed.

Key Details

• Form 8-K filed: September 14, 2026.
• Date of Nasdaq notice: September 11, 2026.
• Regained compliance with: Nasdaq Listing Rule 5550(a)(2) (minimum bid price) and 5550(b)(2) (minimum market value).
• Outstanding issue: deficiency under Nasdaq Listing Rule 5250(c)(1) for delayed periodic SEC filings remains unresolved; Celularity is working to complete those filings.

Why It Matters
Regaining compliance with Nasdaq’s minimum bid price and market-value rules removes the immediate deficiencies referenced by Nasdaq for those specific listing standards, which is a positive development for shareholders. However, the company still has an outstanding deficiency related to late periodic SEC reports; until Celularity completes those filings and Nasdaq confirms compliance, that reporting issue remains open and relevant to investors monitoring the company’s regulatory standing.